CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 99 enrolled
Drug / intervention
Sugammadex +2 moredrug
Likely dose
Sugammadex 0.25 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01006720
NCT01006720N/ACompleted
CompareCT.gov

Dose Finding Study for Sugammadex and Neostigmine at Residual Neuromuscular Blockade (T4/T1 = 0.2)

Technical University of Munich·observational·Posted Nov 3, 2009·Updated Dec 13, 2012

In Brief

An observational study evaluating Sugammadex, Neostigmine, and 1 other intervention for Residual Neuromuscular Block (TOF-ratio of 0.2). Completed, enrolled 99 participants across 1 site.

Detailed Summary

This study is designed to compare recovery times after reversal of a residual neuromuscular block (TOF-ratio 0.2) with different doses of either neostigmine or sugammadex.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsResidual Neuromuscular Block (TOF-ratio of 0.2)
CountriesGermany
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 3, 2009
Enrollment StartMar 1, 2009
Primary CompletionJul 1, 2009
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 16.7 years ago

Interventions

Sugammadexdrug

Single intravenous injection of either: Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 0.75 mg/kg (Sgx 0.75) Sugammadex 1.0 mg/kg (Sgx 1.0) Sugammadex 1.25 mg/kg (Sgx 1.25)

Neostigminedrug

Neostigmine 10 µg/kg (Neo 10) Neostigmine 25 µg/kg (Neo 25) Neostigmine 40 µg/kg (Neo 40) Neostigmine 55 µg/kg (Neo 55) Neostigmine 70 µg/kg (Neo 70)

Salinedrug

Saline 0.9% (Saline)